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SUMMARY 
Neonatal seizures are widely considered a neurological emergency with a need for prompt 
treatment, yet they are known to present a highly elusive target for bedside clinicians.  
Recent studies have suggested that the design of neonatal seizure treatment trial design will 
profoundly influence the sample size, which may readily increase to hundreds or even 
thousands, while the achieved effect size may diminish to clinical irrelevance. The self-
limiting and rapidly resolving nature of neonatal seizures diminishes the achievable treatment 
effect every hour after seizure onset and measured eff cts may be confused with spontaneous 
resolution, precluding the value of many observational studies. The large individual 
variability in seizure occurrence over time and between etiologies challenges group 
comparisons, while the absence of clinical signs mandates quantification of seizure 
occurrence with continuous multi-channel EEG monitoring. A biologically sound approach 
that views neonatal seizures as a functional cot-side b omarker rather than an object to treat 






















Seizures are common in newborns treated in the neonatal i tensive care unit (NICU), 
and are usually considered to require prompt treatmn . The recent introduction of continuous 
video electroencephalography (EEG) monitoring of at-risk infants has made it clear that 
diagnosing neonatal seizures, treating them and following up treatment effects present highly 
elusive targets for bedside clinicians [1–5]. It is now known that clinical recognition of 
neonatal seizures is challenging, or even ambiguous at times, and neonatal seizures vary 
widely with respect to underlying etiology, clinical presentation, and natural time-course, and 
have implications for neurocognitive prognosis [6–10].  
Developing evidence-based guidelines for drug treatm n s calls for studies that 
measure drug effects quantitatively and against an alternative treatment or placebo. In general, 
the ability of a trial to demonstrate treatment success will be highly dependent on design. 
When designing a trial on neonatal seizure treatment, the most important choices include (i) 
the clinically relevant outcome measure(s), (ii) the control group, and (iii) the level of desired 
efficacy. Trial design must also strike a compromise between clinical traditions and practical 
considerations regarding logistical constraints [11]. To the best of our knowledge, there are no 
trials on neonatal seizure treatment that provide an vidence-based sample size calculation 
based on the characteristics of neonatal seizure occurrence. This is entirely understandable as 
detailed knowledge of the time-course of neonatal seizures has only recently become 
available [8].  
In this review, we will first briefly describe the challenge associated with neonatal 
seizure studies, followed by a brief introduction as to how these challenges could be 
addressed in future trials. Finally, we suggest different approaches, including alternative 
attitudes towards clinical perception and handling of neonatal seizures, in order to replace 
ambiguous treatment traditions with evidence-based, individualized medicine. 
2. Trials of neonatal seizure treatment 
A review by Booth and Evans found that only two randomized controlled trials 
(RCTs) for the treatment of neonatal seizures met their selection criteria [12]. Painter et al. 
compared the effectiveness of phenobarbital and phenytoin for the reduction of neonatal 
seizures in a cohort of 59 neonate. The primary outcome measure was complete ‘seizure 
control’ (no seizure burden) observed in the EEG after the target plasma level of free drug had 
been achieved [13]. They found that both phenobarbital and phenytoin controlled seizures in 
approximately 60% of subjects and that there was no difference in effect between these drugs. 













line neonatal seizure treatment in a cohort of 11 neonates (with phenobarbitone as a first line) 
[14]. The primary outcome measure was again ‘seizur control’, which was defined as the 
reduction of seizure burden in the EEG of more than 80% compared to a pre-treatment 
baseline. They found seizure control in 60% of neonates treated with lidocaine and no 
neonates treated with benzodiazepines; however, they did not analyse group differences due 
to the small sample size. These trials show that whereas it may be possible to measure the 
short-term efficacy of a drug treatment for neonatal seizures in a relatively small cohort of 
neonates achievable in real-life trial scenarios, it i  much more difficult, although necessary, 
to determine whether one drug is more effective than another (RCTs with a positive control) – 
a proposition that more closely achieves clinical equipoise [15]. 
Attempts to reinvigorate the pursuit of viable neonatal seizure treatments inspired 
several observational studies of neonatal seizure treatment [16–19]. A large multi-center RCT 
of bumetanide was stopped early due to suspicion of adverse effects [11]; a thorough post-hoc 
reassessment of its findings, together with other recent literature, led to the ideas presented in 
this review paper. Nevertheless, in the 14 years since the review of Booth and Evans, the 
studies of Painter et al. and Boylan et al. remain the only completed RCTs of neonatal seizure 
treatment nearly two decades after their completion [13,14]. 
3. EEG monitoring is obligatory, not optional  
Visual interpretation of the multi-channel EEG is the reference standard for the 
detection of neonatal seizures. The clinical manifestation of seizures is highly variable, 
ranging from no overt clinical signs (also known as subclinical or electrographic) to a myriad 
of behaviours that may readily be confused with non-epileptic movement [6,7]. 
Electroclinical dissociation is also common whereby seizures that initially have clinical 
correlates become electrographic only after neonatal seizure treatment [20,21]. It has been 
well known for decades from older patient groups that e clinical manifestation only reflects 
the functional cortical anatomy of ictal discharge. There is, hence, no biological rationale in 
making therapeutic distinction between seizures with or without clinical signs. 
Outcome measures for neonatal seizure treatment must, therefore, be based on the 
visual interpretation of the multi-channel EEG. The least-biased objective measure of seizures 
for trial outcome is seizure burden, i.e. the accumulated duration of seizure during a period of 
interest [5,13,14,22]. 
It is important to note that seizure detection via visual interpretation of the multi-
channel EEG is not perfect. There are inter- and intra-rater differences in EEG interpretations 
and the EEG only records the activity at the cortical surface, not the deeper structures of the 













monitoring and quality of seizure detection throughout a trial. The first is the use of a 
common electrode placement, as assessment of seizure burden can vary with respect to 
electrode position and the number of electrodes used [23–25]. The annotation of the EEG 
should also be undertaken by several reviewers (ideally the same set of reviewers for each 
subject) who are fully blinded to the trial groups and the timing of clinical events to ensure 
that the variability of EEG interpretation (subjectivity) can be incorporated into the statistical 
analysis of drug efficacy. Subsequent statistical an ysis would then be performed either by 
using the resulting consensus annotations or with multivariate hypothesis test for correlated 
variables such as Hotelling’s T-square test [11,26]. 
The necessity for obtaining EEG recording from as erly, and as long, as possible, sets 
significant challenges to trial logistics. Setting up and maintaining a good quality recording is 
easier with a reduced number of EEG electrodes, whereas seizure analysis is more 
comprehensive with more complex recordings [23–25]. Direct comparison of visual seizure 
detection from different numbers of recording electrodes suggests that the often-used four-
channel EEG recording may be an appropriate solution for striking a compromise between 
these interests [23]. 
Automated seizure detection algorithms could offer an alternative to EEG 
interpretation [27,28]. Their cot-side implementation could accelerate patient recruitment, 
which is crucial for reducing the delay between seizure onset and treatment (see Fig. 1). In 
addition, automated detection would offer an objectiv  alternative to the requirement of labor-
intensive, EEG interpretation by multiple human rate s. 
4. Seizures are self-limiting, and not all seizures are created equal 
It is now well accepted that most seizures in a neonate occur as transient reactions to 
an acute cerebral compromise (asphyxic, ischemic, acute metabolic, infectious). Their onset is 
typically within first days of life, their intensity reflects the underlying cerebral damage, and 
they tend to resolve within tens of hours after onset irrespective of treatment efficacy (see Fig. 
2) [8,29,30]. In contrast, neonatal seizures due to metabolic and/or genetic origin (e.g. the 
neonatal-onset epilepsies) may manifest at more variable times after birth with a time-course 
that no longer spontaneously resolves, and their responses to treatment as well as long-term 
prognosis are determined by the specific underlying molecular pathologies [31–33]. 
These considerations together mean that electroclinical signatures and characteristic 
time-courses of neonatal seizures are too variable between etiologies to allow for a trial 
design that combines them, irrespective of the select d outcome measures. Effective, tailored 
treatments for acute symptomatic neonatal seizures will be distinct from strategies to treat 













would require scaled-up recruitment with massive, long-term multi-centre studies. 
Realistically, the incidence of most neonatal seizur  etiologies is too low for running etiology-
specific treatment studies in a single center within a reasonable time-frame. To be practical, 
trials may need to focus on multiple, related acute symptomatic etiologies (e.g. hypoxic–
ischemic encephalopathy, arterial ischemic stroke, and intracranial hemorrhage), and assess 
antiseizure treatment separately for each etiology. 
In a multi-center setting, it may be possible to recruit reasonable numbers in 
etiological subgroups that comprise the vast majority f all neonatal seizure cases (asphyxia, 
stroke and infection). Such a trial is challenged by the rapid and often erratic natural time-
course of seizure occurrence. These seizures tend to disappear within tens of hours after onset, 
reducing rapidly the chances of capturing a treatmen  success [34]. The fluctuations in 
neonatal seizure occurrence drastically confound the assessment of short-term drug effects 
(within minutes or hours) as chance fluctuations may show apparent changes in seizure 
occurrence that are not a manifestation of the causal relationships with drug treatments. 
Careful inspection of seizure burden time-courses relative to drug dosing may inform a 
subjective judgement in individual cases (see Pressler et al. [11]); however, a therapeutic trial 
requires more objective comparisons with a control g up of some kind. In hindsight, it is 
easy to speculate that many of the findings in pastob ervational studies of neonatal seizure 
treatments may be erroneously reporting the spontaneous disappearance of seizures as 
treatment effects (see Stevenson et al. [34] for an ex mple of this phenomenon in neonates 
and Goldenholtz et al. [35] for a similar result in adult epilepsy) 
5. The critical tetrad: outcome measure, time delays, control group, and effect size 
Once the cohort of interest and treatment protocol have been decided, investigators 
must consider four factors that will affect the sample size required for a successful trial: the 
outcome measure, the average time between drug administration and seizure onset, the type of 
control group, and the desired effect size (see Fig. 1). The effects of these factors on the 
sample size of the RCT have previously been evaluated using computer simulations; a 
technique which has become increasingly popular as n evidence-based tool for RCT design 
[34,36]. Simulation has shown that the required sample size increases rapidly when the trial 
uses positive control groups (i.e. an existing drug of some efficacy), targets a larger effect 
size, or if there is a longer delay from seizure onset to the drug administration. The choice of 
outcome measure, in conjunction with these other factors, may result in trial sample sizes 
ranging from tens to tens of thousands [34]. 
Moreover, the nonlinear effect of time delay on sample size (see Fig. 1) means that 













against an active treatment rather than placebo [34]. Increases in the required sample size are 
also apparent in cohorts treated with therapeutic hypothermia or other seizure-attenuating 
treatments, as the reduction in overall seizure burden educes the potential treatment effect 
[37,38]. 
6. Logistic challenges call for alternative approaches 
An evidence-based neonatal seizure trial design is theoretically possible by accounting 
for the implications of the critical tetrad described above. The practical constraints are, 
however, many: the numbers of infants available in one trial site are limited; there is a need 
for continuous prospective multi-channel EEG monitoring and its blinded visual analysis; the 
effect size may be small, making its reliable measurement difficult when EEG interpretation 
is subjective; it may be very challenging to run the rial protocol with sufficiently short time-
delays in the midst of busy NICU routines. These constraints result in a rapidly escalating 
sample size to compensate for compromises in trial design. In this case, it becomes appealing 
to revisit alternative ways to perceive neonatal seizur s.  
Despite significant efforts in experimental and clini al studies, it has remained 
challenging to prove that neonatal seizures cause brain damage in the NICU setting, or to 
prove that effective neonatal seizure treatment improves neurocognitive outcomes [39,40]. In 
contrast, several clinical studies support the notion hat seizures are associated with 
underlying brain damage and/or etiology, and the mere presence of seizures in the context of 
brain damage is predictive of neurocognitive outcome [41–43]. Therefore, neonatal seizures 
can be considered as a de-facto cot-side biomarker of newborn brain function.  
Perceiving neonatal seizures as a biomarker rather than an object-to-treat would 
dramatically change views on seizure management. Such perception allows a more flexible, 
clinically adjusting, and context-aware (e.g. etiology specific) approach; the fundamental 
basis of modern personalized medicine. It would also lead to immediate opportunities for 
implementing automated seizure detection algorithms into clinical EEG monitors which is 
currently impeded by legal concerns relating to potential misdiagnosis, a worry caused by the 
implicit, yet unproven ethos among clinical community that neonatal seizures mandate 
treatment [5,27].  
Modern day NICUs are already taking advantage of EEG monitoring of neonatal 
seizures for individualized neurological assessment (HIE scoring), therapeutic targeting, as 
well as early prognostication [44–47]. As a spin-off from this non-selective monitoring 
practice, it has recently become clear that non-pharmacological treatments, such as 
therapeutic hypothermia for HIE, may significantly reduce seizure burden, in addition to their 













difficulty of implementing neonatal seizure drug trials and reduce the clinical significance of 
any measured effects.   
7. Conclusions 
Assessing the efficacy of treatments for neonatal seizures is not a trivial task. Seizures 
are difficult to identify, highly variable (over time and over patients) and self-limiting. 
Furthermore, the very idea of trialing a treatment is overshadowed by a dearth of evidence on 
the causal relationship between seizures and neurodvelopmental outcome.  
Analysis of previous RCTs combined with advances in our knowledge of the time-
course of neonatal seizures provides insights that can aid future trial designs. We can now see 
that a control group is needed to measure the treatment effect, the choice of outcome measure 
is critical, and the outcome measure needs to be proximal enough to find any differences.  
Although attempts to study individual drug effects on neonatal seizures may not 
translate ideally to clinical practice, future trials on infants with neonatal seizures will be 
challenged to define optimal holistic therapeutic conditions. In this case, seizures will be 
treated as a functional cot-side biomarker rather tan as a disease per se, and the effect of 
therapy can be measured from the change in clinical outcomes rather than the occurrence of 
neonatal seizures. 
Finally, the overall ideas in the present paper apply to any trial that aims to treat self-
limiting symptoms, such as migraine, status epilepticus, lower back pain, or paediatric otitis 
[48–51]. 
Practice points 
• Neonatal seizures present a challenging target for treatments due to their rapid natural 
time-course and high individual variability. 
• Quantifying seizure burden from multi-channel EEG recordings is necessary to assess the 
efficacy of seizure treatment. 
• The most important factors of choice in a neonatal seizure trial design include the 
outcome measure, the control group, and the delay from seizure onset to trial 
intervention. 
• Trial design, notably the speed of trial protocol execution, will profoundly influence the 
required sample size. 
• Trial simulations with etiology-specific seizure burden profiles are crucial for evidence-
based trial design. 
Research directions 
• Characterization of the natural course of neonatal seizures in different etiologies. 













• Prove the value of neonatal seizure treatment for neu odevelopment. 
• Evaluate the use of neonatal seizures as a biomarker rather than as an object to treat.  
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Fig. 1. Assessing neonatal seizure treatment drug efficacy and sample size in a randomized 
controlled trial. (A) Schematic examples of the temporal evolution of seizures for three 
potential treatments: a placebo control, positive control, and the trial drug. The time-periods 
used to calculate seizure burden are defined in the outcome measure. The outcome measure is 
compared between selected groups using a statistical test. (B) The effects of outcome measure 
(OM), control group, and time delays on the required sample size. OM1 is a trial that 
measures total recorded seizure burden in a neonate, OM2 is the seizure burden post treatment 
(assessed within a 12 h period), and OM3 is the relativ  reduction in seizure burden between a 
pre-treatment period (1 h) and post-treatment period (12 h). The upper bound is for a trial 
with positive controlled trial; the lower bound is for a placebo controlled trial. The simulated 
effect in this example is an 80% reduction in seizures for 72 h after treatment. Results are 
based on computer simulations of trials with seizure time-courses similar to that shown in Fig. 
2. EEG, electroencephalography; SB, hourly seizure b den. 
Fig. 2. The evolution of neonatal seizures from recorded seizure onset. (A) An example time-
course of seizures in a neonate with hypoxic–ischemic ncephalopathy (HIE); the hour-by-
hour assessment of seizure burden (blue line) fluctuates unpredictably, but its general trend 
follows a lognormal curve with a rapid increase in seizure burden followed by a slow decay 
(black line). The hourly seizure burden has been calculated from the raw annotation of actual 
seizure occurrence (orange line). (B) Time-courses of neonatal seizures from a cohort of 
neonates with HIE (N = 41). Note the considerable variability in seizures over time and 
between neonates. (C) An alternative representation of the seizure time-courses in a subset of 
neonates with HIE (N = 21); each trace represents the seizure time-course from a single 
neonate where the width of the trace is proportional to the hourly seizure burden. 
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